Pharma — Februar 2025
-
Lundbeck OVERBLIK Q4: Omsætning skuffer let men nyeste lægemiddel fortsætter vækst https://proinvestor.com/investornyt/1274030/lundbeck-overblik-q4-omsaetning-skuffer-let-men-nyeste-laegemiddel-fortsaetter-vaekst
-
Lundbeck sigter efter vækst fra driften på 5-11 pct. i 2025 - opkøb gør indhug https://proinvestor.com/investornyt/1274044/lundbeck-sigter-efter-vaekst-fra-driften-pa-5-11-pct-i-2025-opkob-gor-indhug
-
Lundbeck får tildelt hastebehandling af middel mod MSA i USA https://proinvestor.com/investornyt/1277195/lundbeck-far-tildelt-hastebehandling-af-middel-mod-msa-i-usa
-
Over halvdelen af ansøgninger om nye lægemidler handler om kræftmedicin https://www.dr.dk/nyheder/seneste/over-halvdelen-af-ansoegninger-om-nye-laegemidler-handler-om-kraeftmedicin
-
-
ALK's topchef om regnskabstal: Europæiske tabletsalg fortsætter frem - har haft mindre skuffelse i USA https://proinvestor.com/investornyt/1280132/alks-topchef-om-regnskabstal-europaeiske-tabletsalg-fortsaetter-frem-har-haft-mindre-skuffelse-i-usa
-
ALK's topchef om toldtrussel: Det er i småtingsafdelingen for os https://proinvestor.com/investornyt/1280154/alks-topchef-om-toldtrussel-det-er-i-smatingsafdelingen-for-os
-
ALK får godkendt behandling til yngre børn af amerikanske sundhedsmyndigheder https://proinvestor.com/investornyt/1284667/alk-far-godkendt-behandling-til-yngre-born-af-amerikanske-sundhedsmyndigheder
(aflibercept). Teva stiger 7% i formarkedet.Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind